Topic Listing for Hi-Tech Pharmacal

Accounts Receivable Accrued Expenses Other Current Liabilities
Acquisition Intangible Asset Adopted Pursuant 302 Sarbanes-oxley Act 2002
Advertising Expense Aggregated Option Exercises Last Year-end Values
Agreement Amended Restated Stock Option Plan
Amendment Anda Process
Annex Annual Report
Applicable Only Corporate Issuers Approved Products Not Achieve Expected Levels Market Acceptance
Asset Purchase Agreement Audit Audit-related Fees
Audit Committee Audit Committee Financial Expert
Audit Committee Report Audit Fees
Audit Related Fees Auditor Fees
Available Information Balance Sheet Data
Basis Accounting Principles Consolidation Basis Presentation
Basis Presentation Restated Bayview Avenue Amityville New York 11701
Beneficial Ownership Reporting Compliance Board Directors Compensation Committee
Board Directors Recommends Vote Each Nominee Branded Prescription Products
Bryce Harvey President Midlothian Division Business
Business Acquisition Cash Equivalents
Certain Relationships Related Transactions Certain Transactions
Certification Pursuant Rule 13a-14 15d-14 Securities Exchange Act Certifications
Changes Internal Control Over Financial Reporting Code Ethics
Commitments Commitments Contingencies
Commitments Contingencies Other Matters Committees
Committees Meetings Board Directors Common Stock
Common Stock Holders Communications Directors
Compensation Chief Executive Officer Compensation Committee Charter
Compensation Committee Interlocks Insider Participation Compensation Committee Report
Compensation Discussion Analysis Compensation Philosophy
Competition Components Executive Compensation Program
Comprehensive Income Condensed Statements Cash Flows
Condensed Statements Operations Conditions Precedent Purchasers Obligation Close
Connection 2008 Annual Meeting Stockholders Connection 2009 Annual Meeting Stockholders
Consent Independent Auditor Consent Independent Registered Public Accounting Firm
Consolidation Customers Contents
Contingencies Other Matters Contingent Purchase Price
Contractual Obligations Off-balance Sheet Arrangements Controls Procedures
Corporate Governance Cost Sales
Credit Facility Critical Accounting Policies
Currently Sell Numerous Prescription Not Require Fda Approval Customer Deposits Contract Research Income
Customers Marketing David Seltzer Chairman Board President Chief Executive Officer
Davis Caskey Vice President Pharmaceutical Operations Dea
Deferred Tax Assets Liabilities Composed Following Delays New Product Introductions
Director Compensation Directors Compensation
Directors Plan Directors Stock Option Plan
Dividends Earnings Loss Per Share
Earnings Per Share Ecr Pharmaceuticals
Employee Benefit Plan Employee Stock Option Plan
Employees Employment Agreement
Employment Agreements Employment Contracts
Environment Equity Compensation Plan Information
Estimates Evaluation Disclosure Controls Procedures
Exact Name Registrant Specified Charter Executive Officers
Executive Officers Directors Significant Employees Exhibits
Expected Tax Expense Based Statutory Rate Reconciled Actual Expense
Expense Income Explanatory
Facilities Fair Value Financial Instruments
Fair Value Measurements Fda Oversight
Financial Information Systems Design Implementation Fees Fixed Assets
Form 10-k Form 10-q
Former Name Address Changed Since Last Report Forward Looking Statements
Freight Expense Gary President Health Care Products Division
General Generic Approvals Product Launches
Generic Products Government Regulation
Grants Plan-based Awards Growth Strategy
Health Care Products Division Held 2005
Held 2006 Held 2007
Held 2008 Held 2009
Hi-tech Pharmacal Inc I-definitions
Ii-disclosure Scientific Technical Information Confidentiality Iii-supply Product
Important Notice Regarding Availability Proxy Materials Stockholders Meeting Income Analysis
Income Taxes Incorporation Reference
Increase 200000 Number Shares Reserved Issuance Thereunder Indemnification Obligations
Independence Directors Independent Auditors Report
Index Exhibits Individual Grants
Industry Highly Competitive Industry Highly Competitive Competitors Cause Pricing Declines Loss
Intangible Assets Introduction
Inventories Inventory
Investment Neuro-hitech Investment Neuro-hitech Restated
Iv-product Prices Payment Terms Ix-rights Duties After Termination
Legal Proceedings License Agreement
Limited Number Major Customers Limited Number Manufacturing Facilities
Liquidity Capital Resources Long Term Debt
Long-lived Assets Major Customers
Management Report Internal Control Over Financial Reporting Management Report Internal Control Over Financial Reporting Restated
Managements Report Internal Control Over Financial Reporting Manufacture Majority Generic Products Some Over Counter Brands
Manufacturing Market Information
Marketable Securities Medicaid Medicare
Membership Name Person Filing Proxy Statement Other Registrant
Naprelan Naprelan License Agreement
Nature Business Significant Accounting Policies Net Earnings Per Share
Net Income Loss Per Share Net Income Per Share
Net Loss Earnings Per Share Net Loss Per Share
New Accounting Pronouncements Nominating Committee
Nominees Director Non-competition Non-solicitation Agreement
Notes Financial Statements Now Therefore
Number 0-20424 Objectives Philosophy Executive Compensation Program
Obligation Capital Lease Obligation Close
Once Approved New Products Not Achieve Expected Levels Option Exercises Holdings
Options Exercises Stock Vested Other Agreements Parties
Other Assets Other Business
Other Fees Other Matters
Outstanding Equity Awards Year-end Part
Part Other Information Party Suppliers
Patent Challenge Process Performance Graph
Pipeline Products Development Subject Regulatory Delays Fda Key Policies Code Ethics
Policy Audit Pre-approval Permissible Non-audit Services Independent Auditor Potential Payments Termination Employment Change Control
Pre-approval Policies Principal Accounting Fees Services
Pro Forma Condensed Consolidated Financial Information Pro Forma Financial Statements
Procedures Proceedings Preceding
Product Development Strategy Product Divestiture
Product Divestitures Product Liability
Properties Property Equipment
Proposal Adoption 2009 Stock Option Plan Fifteen Term Proposal Amendment Amended Restated Stock Option Plan Increase
Proposal Election Directors Proposal Ratification Independent Auditors
Proposals Annual Meeting Provision Benefit Income Taxes Comprised Following
Provision Income Taxes Comprised Following Proxy
Purchase Sale Purchased Assets Purpose Authority Responsibilities
Quantitative Qualitative Disclosures Market Risk Raw Materials Active Pharmaceutical Ingredients
Recent Accounting Pronouncements Recent Approvals Product Launches
Recent Events Recent Sales Unregistered Shares
Recitals Registrant
Related Party Transactions Reliant Party Suppliers Active Ingredients Products Prolonged Interruption
Remediation Material Weakness Remediation Material Weaknesses
Remediation Material Weaknesses Restated Report Independent Registered Public Accounting Firm
Report Independent Registered Public Accounting Firm Schedule Representations Warranties Purchaser
Research Development Research Development Costs
Responsibilities Restatement
Results Results Operations 2004 2003
Results Operations 2005 2004 Results Operations 2005 Compared 2004
Results Operations 2006 2005 Results Operations 2006 Compared 2005
Results Operations 2007 2006 Results Operations 2007 Compared 2006
Results Operations 2008 2007 Results Operations 2008 Compared 2007
Results Operations 2009 2008 Revenue
Revenue Recognition Review Approval Ratification Transactions Related Persons
Revisions Charter Revolving Credit
Revolving Credit Term Loan Agreement Risk Approved Products Not Achieve Expected Levels Market
Risk Factors Risk New Product Introductions
Role Independence Royalty Payment
Sales Products Adversely Affected Continuing Consolidation Customers Sarbanes-oxley Act 2002
Savings Plan Seasonality
Securities Exchange Act 1934 Securities Exchange Washington 20549
Securities Registered Pursuant Act Common Stock Par Value See
Signatures Significant Customers Concentration Credit Risk
Significant Employees Specifications
State New York County Suffolk State Other Jurisdiction Incorporation
Stock Buy-back Program Stock Option Plan Activity
Stock Option Plans Stock Options
Stock Split Stock-based Compensation
Stockholder Proposals 2009 Annual Meeting Stockholder Proposals 2010 Annual Meeting
Subject Government Regulation Fda Dea Face Significant Costs Submission Matters Vote Security Holders
Subsequent Event Subsequent Events
Summary Compensation Table Supply Agreement Dorzolamide Hydrochloride
Tax Considerations Tax Fees
Termination Title Class
Top Generic Products Unapproved Products
Uncertainties Estimates Assumptions Unregistered Sales Equity Securities Proceeds
Unregistered Sales Equity Securities Proceeds Issuer Purchases Uses Multiple Contract Manufacturers Supply Products Not Hi-techs
V-quality Controls Valuation Qualifying Accounts
Vi-representations Warranties Vii-indemnity Recalls
Viii-term Termination Voting Procedures
Website Access Filings Securities Exchange Whereas
Whether Not Expect Attend Meeting Urge Sign Date William Peters Vice President Chief Financial Officer
Witness Whereof Working Capital Revolving Loan
X-force Majeure Xi-miscellaneous
Xii-governing Law Arbitration Year-end Option Values
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki